ACT Venture Partners

ACT Venture Partners is a specialised Turkish deep-tech venture firm headquartered in Istanbul, deploying $250k-$1M cheques across pre-seed, seed, Series A, and Series B into technical founders solving foundational problems in computational biology, advanced materials, AI drug discovery, biotech, diagnostics, and medical devices. The firm differentiates through deep technical underwriting (the partner team carries genuine scientific and engineering credibility) and patient capital matched to deep-tech development cycles. For founders, ACT is one of the few Turkish funds with the technical bench to underwrite genuinely deep biotech and AI drug discovery bets, making it a category-defining specialist in the region. The right founder profile is a technically credible Turkish or regional founder, often with PhD or strong research pedigree, building a defensible biotech, AI drug discovery, computational biology, or medical device platform with early validation and a clear regulatory pathway. Founders running consumer wellness, asset-heavy clinic models, or pure commercial plays without technical depth are a poor fit. Entry path is via the Turkish deep-tech ecosystem (Bogazici, METU, Koc), an ACT portfolio CEO, or warm introductions from European and Israeli deep-tech specialists that co-invest. In the pitch, lead with technical defensibility, IP strategy, regulatory positioning through TITCK, FDA and EMA, clinical or experimental validation roadmap, and a credible international expansion plan. Caveats: deep-tech investing requires patient capital and longer cycle times to commercial maturity, and Turkey’s macro and FX volatility create structural follow-on capital constraints, so founders should plan European, US, or Gulf leads early at Series A and beyond. ACT’s brand carries growing weight in regional deep-tech but founders should pair with international co-leads for cross-border scaling. Confirm reserves and follow-on policy explicitly during initial diligence.